TransMedics Group Inc (TMDX) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Total Revenue Chart for TransMedics Group Inc
TransMedics Group Inc (TMDX) revenue for FY2025 was USD 605.5M, a 37.1% change from FY2024. TransMedics Group Inc's revenue grew from USD 6.2M in 2016 to USD 605.5M in 2025 (9651.9% over 9 years). Earnings per share moved from USD -1.66 in 2016 to USD -1.23 in 2022. Revenue compound annual growth rate: 5-year CAGR of 88.2%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $2.45B
- Implied Share Price
- $70.74
- Enterprise Value
- $4.08B
- Revenue (TTM)
- $668.47M
- EBITDA
- $115.63M
- Profit Margin
- 22.69%
- Trailing P/E
- 18.33
- Forward P/E
- 52.36
- Price/Book (MRQ)
- 12.44
- Price/Sales (TTM)
- 3.67
- EV/EBITDA
- 36.40
- EV/Revenue
- 7.67
- Dividend Yield
- —
- Book Value
- $14.96
- Free Cash Flow (FY2025)
- $133.59M
- Free Cash Flow Yield
- 5.45%
Snapshot as of 25th October 2026 — not point-in-time controlled, may lag the live market by a few days.